Posted in | Pharmaceuticals and Drug Discovery

Enhancing assay precision for small molecule bioanalysis

From Feb 27 2025

This on-demand webinar takes a closer look at the analytical challenges of LC-MS bioanalysis for low molecular weight molecules (under 200 amu) – a common hurdle in metabolomics, biomarker studies, and tracking metabolic products of drug biotransformation.

Topics covered:

  • How low molecular weight properties shape bioanalytical strategies
    • The role of hydrophilicity and lipophilicity in extraction and separation
    • Enhancing MS sensitivity through assay design and derivatization
  • Case studies on assays developed for small molecule targets
    • Examples of successful bioanalytical approaches for low molecular weight compounds

About the speakers

  • Hermes Licea-Perez – Scientific Director and Technology Leader at GSK
  • Jing Lai, Ph.D. – Associate Director ADME at Pharmaron
  • Moderated by Scott Summerfield – Senior Director Pharmaceutical Metabolism at Pharmaron

Other Webinars from Pharmaron

Key considerations for dosimetry from non clinical to clinical application

Key considerations for dosimetry from non clinical to clinical application
Scaling up API production: How to balance speed with supply chain security

Scaling up API production: How to balance speed with supply chain security
The principles of macrocyclic drug discovery

The principles of macrocyclic drug discovery
Smarter drug design with molecular glues

Smarter drug design with molecular glues
Exploring CK1 degrader discovery and molecular glue technologies

Exploring CK1 degrader discovery and molecular glue technologies
Practical in vitro insights into low clearance compounds

Practical in vitro insights into low clearance compounds
Advancing hADME with modern AMS tools

Advancing hADME with modern AMS tools
Data-driven or physics-based: Choosing the smarter approach to DMPK modeling

Data-driven or physics-based: Choosing the smarter approach to DMPK modeling
What’s changing in DDI guidance? A closer look at ICH M12

What’s changing in DDI guidance? A closer look at ICH M12
Strategies for the successful development of antibody drug conjugates

Strategies for the successful development of antibody drug conjugates
Key ADME and DMPK insights for oligonucleotide drug development

Key ADME and DMPK insights for oligonucleotide drug development

Life Science Webinars by Subject Matter

Watch the
Webinar

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback